CLN6 anticorps (C-Term)

N° du produit ABIN634889

L’anticorps Lapin Polyclonal anti-CLN6 a été validé pour WB. Il convient pour détecter CLN6 dans des échantillons de Humain, Souris, Rat et Chien.

Aperçu rapide pour CLN6 anticorps (C-Term) (ABIN634889)

Antigène: CLN6 (Ceroid-Lipofuscinosis, Neuronal 6, Late Infantile, Variant (CLN6))

Reactivité: Humain, Souris, Rat, Chien

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp CLN6 est non-conjugé

Application: Western Blotting (WB)

Détail du produit anti-CLN6 anticorps

Épitope: C-Term

Specificité: CLN6 antibody was raised against the C terminal of CLN6

Purification: Affinity purified

Immunogène: CLN6 antibody was raised using the C terminal of CLN6 corresponding to a region with amino acids RLFLDSNGLFLFSSFALTLLLVALWVAWLWNDPVLRKKYPGVIYVPEPWA

Information d'application

Indications d'application: WB: 1 µg/mL
Optimal conditions should be determined by the investigator.

Commentaires:

CLN6 Blocking Peptide, (ABIN5612933), is also available for use as a blocking control in assays to test for specificity of this CLN6 antibody

Restrictions: For Research Use only

Stockage

Format: Lyophilized

Reconstitution: Lyophilized powder. Add distilled water for a 1 mg/mL concentration of CLN6 antibody in PBS

Concentration: Lot specific

Buffer: PBS

Conseil sur la manipulation: Avoid repeated freeze/thaw cycles.
Dilute only prior to immediate use.

Stock: 4 °C/-20 °C

Stockage commentaire: Store at 2-8 °C for short periods. For longer periods of storage, store at -20 °C.

Détails sur CLN6

Antigène: CLN6 (Ceroid-Lipofuscinosis, Neuronal 6, Late Infantile, Variant (CLN6))

Autre désignation: CLN6

Sujet: CLN6 is one of eight which have been associated with neuronal ceroid lipofuscinoses (NCL). Also referred to as Batten disease, NCL comprises a class of autosomal recessive, neurodegenerative disorders affecting children. The genes responsible likely CLN6 involved in the degradation of post-translationally modified proteins in lysosomes. The primary defect in NCL disorders is thought to be associated with lysosomal storage function.

Poids moléculaire: 36 kDa (MW of target protein)

Pathways: Glycosaminoglycan Metabolic Process